Orchid Pharma Ltd.

₹523.8

4.5 (0.9%)

ORCHPHARMA Share Price

Pharmaceuticals & Biotechnology

As on April 2, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 2,657 Cr

P/E Ratio26.66

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	511.9	Bullish
10-DMA	516.76	Bullish
20-DMA	519.97	Bullish
50-DMA	613.06	Bearish
100-DMA	710.59	Bearish
200-DMA	721.71	Bearish

Historical Performance

1 Year

-34%

3 Years

36.7%

5 Years

-79.3%

10 Years

1267.6%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	9,219	8,194	6,659	5,596	4,501
Total Expenditure	8,113	7,086	5,816	5,050	3,994
Other Income	344	311	194	90	152
Operating Profit	1,450	1,419	1,037	636	659
Interest	149	167	329	335	522
Depreciation	345	332	548	870	1,089
Profit Before Tax	956	919	552	-569	-952
Consolidated Net Profit	997	922	463	-20	-1,165
Adjusted EPS	20	18	11	---	-29

Compounded Sales Growth

10 Years:-12

5 Years:13.8

3 Years:10.5

TTM:2.4

Compounded Profit Growth

10 Years:-29.4

5 Years:-23.4

3 Years:77.7

TTM:1.6

Stock Price CAGR

10 Years:29.9

5 Years:-27

3 Years:10.8

TTM:-34.2

Return on Equity

10 Years:-31.4

5 Years:-28.5

3 Years:11.3

last year:19.6

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	507	507	408	408	408
Total Reserves	12,166	11,187	6,478	6,066	6,121
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	1,350	1,244	1,647	2,224	4,423
Other Current Liabilities	185	143	531	472	258
Short Term Borrowings	426	140	1,410	228	28
Total Liabilities	16,878	15,539	12,252	11,106	12,373
Capital Work in Progress	645	164	465	98	74
Long Term Loans & Advances	1,174	664	602	739	91
Currents Investments	---	---	---	---	150
Short Term Loans and Advances	540	574	225	201	959
Total Current Assets	8,073	7,908	5,010	3,844	4,290
Total Assets	16,878	15,539	12,252	11,106	12,373
Adjusted Book Value	250	231	169	159	160

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 26.66, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a moderate 3-year price CAGR of 10.8%, reflecting average market performance.
The stock carries a high beta of 1.3, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹1450 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹9219 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 658081.5

No. of Shares: 1256 (Approx)

Performance:-34.2%

P/L: ₹-341918.5

NIFTY Performance: -2.3%

1 day Top Gainers